The identification of the mechanisms underlying increased sensitivity to NRP1 disruption in ECs with reduced β3-integrin expression should enable the rational design of intervention strategies to improve anti-angiogenic outcomes in patients with advanced cancers. The gene discussed is NRP1; the disease is cancer.